FDA: Page
-
Teva's internal probe turns up 'likely' corruption
Teva affiliates in Russia and other countries may have provided false information to local authorities about marketing and promotions.
By Nicole Gray • Feb. 12, 2015 -
EMA defends data black-out policy for AbbVie's Humira
Transparency experts are fuming over the European Medicine Agency's decision to omit certain data from a Humira Clinical Study Report (CSR).
By Nicole Gray • Feb. 12, 2015 -
Riken stem cell saga continues as Obokata and other scientists face reprimands
The government-funded Japanese research institution is blaming scientist Haruko Obokata and three of her research colleagues for publishing false data in top journals, including Nature.
By Nicole Gray • Feb. 12, 2015 -
Former Merck financial analyst to plead guilty to insider trading
Between 2012 and 2014, Zachary Zwerko passed confidential information about three stocks to a product manager at BNY Mellon.
By Nicole Gray • Feb. 11, 2015 -
Nanotrending: FDA adopts another nanotech standard
Since January 2014, the FDA has adopted three nanotech standards—representing a new area of regulation and a new era of nanomedicine.
By Nicole Gray • Feb. 11, 2015 -
Another one bites the dust: FDA to revoke breakthrough status for BMS hep C med, too
With Gilead and AbbVie as front-runners in the brave new world of hepatitis C treatments, BMS is joining Merck at the back of the line.
By Nicole Gray • Feb. 11, 2015 -
Former MN gov demands more trial transparency at UMN in wake of '04 suicide
Former Gov. Arne Carlson also called for additional details about the death of a University of Minnesota study subject in 2004.
By Nicole Gray • Feb. 11, 2015 -
Merck fights back after BC Health Ministry drops diabetes drug
Merck fielded a survey in which 85% of doctors said that drug substitution on economic grounds is bad for patients in light of the agency's decision to drop a diabetes med.
By Nicole Gray • Feb. 10, 2015 -
Roche's blockbuster Lucentis nabs fourth FDA approval
Lucentis is now cleared for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
By Nicole Gray • Feb. 9, 2015 -
FDA proposes new consumer-friendly print drug ad guidance
After years of requiring comprehensive warnings in package inserts, the FDA is endorsing warnings on drug labels that highlight the most serious risks and use less technical language.
By Nicole Gray • Feb. 9, 2015 -
Arkansas settles Vertex Medicaid suit over pricey Kalydeco
The state will no longer require cystic fibrosis (CF) patients to use standard therapy for 12 months before becoming eligible for Kalydeco (ivacaftor), a $311,000-per-year drug.
By Nicole Gray • Feb. 9, 2015 -
Why the FDA wants to double inspectors at Indian manufacturing facilities
It's not because of the manufacturing-related issues you might suspect.
By Nicole Gray • Feb. 6, 2015 -
FDA simplifies compassionate use process in a big way
Many physicians have complained that the amount of documentation required by the Expanded Access Program is cumbersome.
By Nicole Gray • Feb. 6, 2015 -
NY Attorney General nabs price reduction for heroin-fighting naloxone
The price of naloxone, which is used as a heroin antidote, doubled last fall, putting tremendous pressure on health officials who treat addicts.
By Nicole Gray • Feb. 6, 2015 -
Deep Dive
Passing the torch: Ralph Neas' tenure at the Generic Pharmaceutical Association
After four years, Ralph Neas, CEO and President of GPhA, is stepping down. So what does it take to run the organization? A great deal of experience and the ability to stay on message.
By Nicole Gray • Feb. 5, 2015 -
Study: Drug makers fail to meet adverse-event reporting requirements
According to a study by the Institute for Safe Medication Practices, only half of reports on serious side effects submitted by drug makers are complete.
By Nicole Gray • Feb. 5, 2015 -
UPDATED: FDA chief Hamburg to resign at end of March
Hamburg oversaw a period of major changes to the agency, including the advent of the ACA and Food Safety Modernization Act.
By Sy Mukherjee • Feb. 5, 2015 -
Trans-Pacific Partnership trade talks fail to resolve patent & IP issues
The U.S. wants 12 years of protection. Emerging markets want about seven. Can negotiators bridge the gap?
By Nicole Gray • Feb. 5, 2015 -
Pfizer on fire with early FDA nod for blockbuster Ibrance, $15B Hospira buyout
The company has been struggling with past and pending patent expirations. But the events of the last two days go a long way towards addressing that.
By Nicole Gray • Feb. 5, 2015 -
Merck's hep C treatment loses FDA breakthrough status
Blame Sovaldi, Harvoni, and Viekira Pak.
By Nicole Gray • Feb. 5, 2015 -
Another FDA warning letter for India-based Apotex
The letter cites serious manufacturing violations.
By Nicole Gray • Feb. 4, 2015 -
UK first in world to legalize '3-person DNA' babies to curb genetic disorders
UK's Parliament made history on Tuesday by approving a law that would allow babies to be created from the DNA of two women and one man.
By Sy Mukherjee • Feb. 3, 2015 -
FTC: Ranbaxy must sell acne drug to Torrent Pharma before Sun takeover
As the proposed acquisition of Ranbaxy by Sun Pharmaceuticals moves forward, the U.S. Federal Trade Commission is enforcing an anti-competitive requirement.
By Nicole Gray • Feb. 3, 2015 -
Sponsored by
Active Pharmaceutical Ingredient Detection Using Spectrophotometers: An Investment that Pays Off
Sponsored by: Knowing the active pharmaceutical ingredients in your over-the-counter and prescription medications is a must in today’s health care industry. Mistakes in prescriptions, miscalculated doses, and drug interactions are all genuine concerns in a world where drug choices and ...
Feb. 3, 2015 -
FDA approves new Zohydro ER pankiller formulation
The new version of Zohydro ER features a new type of abuse-deterrence, Beadtek. Despite this feature, critics are complaining that there are not sufficient data to ensure abuse deterrence.
By Nicole Gray • Feb. 3, 2015